sur Lir Life Sciences Corp. (CVE:SKNY)
Lir Life Sciences Announces New Study on Obesity Therapies
Lir Life Sciences Corp., based in Vancouver, has unveiled the design of a comparative animal study. This research focuses on cell-penetrating peptide-mediated delivery of GLP/GIP-based obesity therapies. The study aims to advance Lir's transdermal platform, promoting needle-free options for obesity treatments. GLP-1 and GIP improve metabolism and weight regulation, targeting obesity's core factors.
The study, in collaboration with scientific partners, aims to assess transdermal delivery effectiveness compared to traditional injections. Subjects will receive transdermal formulations followed by an oral glucose challenge. Success will be measured by monitoring blood glucose levels.
The results will guide Lir's future research, identifying the most promising drug candidates for further development. CEO Edward Mills emphasizes the goal to find the best candidates for transdermal delivery, influencing their IND strategy.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Lir Life Sciences Corp.